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Abstract
Rheumatoid arthritis (RA) is characterized by inflammation and
an increased risk for cardiovascular disease (CVD). This study
investigates possible associations between CVD and the use of
conventional disease-modifying antirheumatic drugs (DMARDs)
in RA. Using a case control design, 613 RA patients (5,649
patient-years) were studied, 72 with CVD and 541 without CVD.
Data on RA, CVD and drug treatment were evaluated from time
of RA diagnosis up to the first cardiovascular event or the end of
the follow-up period. The dataset was categorized according to
DMARD use: sulfasalazine (SSZ), hydroxychloroquine (HCQ) or
methotrexate (MTX). Odds ratios (ORs) for CVD, corrected for
age, gender, smoking and RA duration, were calculated per
DMARD group. Patients who never used SSZ, HCQ or MTX
were used as a reference group. MTX treatment was associated
with a significant CVD risk reduction, with ORs (95% CI): 'MTX
only', 0.16 (0.04 to 0.66); 'MTX and SSZ ever', 0.20 (0.08 to
0.51); and 'MTX, SSZ and HCQ ever', 0.20 (0.08 to 0.54). The
risk reductions remained significant after additional correction
for the presence of rheumatoid factor and erosions. After
correction for hypertension, diabetes and hypercholesterolemia,
'MTX or SSZ ever' and 'MTX, SSZ and HCQ ever' showed
significant CVD risk reduction. Rheumatoid factor positivity and
erosions both increased CVD risk, with ORs of 2.04 (1.02 to
4.07) and 2.36 (0.92 to 6.08), respectively. MTX and, to a lesser
extent, SSZ were associated with significantly lower CVD risk
compared to RA patients who never used SSZ, HCQ or MTX.
We hypothesize that DMARD use, in particular MTX use, results
in powerful suppression of inflammation, thereby reducing the
development of atherosclerosis and subsequently clinically
overt CVD.
Introduction
Cardiovascular diseases (CVDs) are the most important cause
of death in patients with rheumatoid arthritis (RA). RA is asso-
ciated with a significant increase in cardiovascular morbidity
and mortality compared to the general population [1-7]. A
clear explanation for this excess in cardiovascular risk is lack-
ing, although several causes have been postulated. First, an
increased prevalence of established cardiovascular risk fac-
tors, such as hypertension, diabetes and hypercholestero-
lemia. Second is the possibility of under-treatment of
cardiovascular co-morbidity [8,9]. Third, RA itself could be
responsible for the excess in cardiovascular morbidity and
mortality, either by a decreased functional capacity [10], or by
the underlying inflammatory process. There is growing evi-
dence that atherosclerosis is an inflammatory disease [11,12].
Moreover, inflammation might cause deterioration of fatty
streaks into (unstable) plaques [13] and can lead to plaque
ruptures [14], as well as to complement activation [15] or facil-
itate deterioration of the lipid profile [16], all important aspects
in the pathogenesis of atherosclerosis.
A complex element in the association between RA and cardi-
ovascular risk is the use of antirheumatic medication. Patients
with persisting disease activity require treatment with disease-
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modifying antirheumatic drugs (DMARDs) [17]. There are
some indications that DMARDs can alter cardiovascular risk
either by influencing atherosclerotic processes directly
through inflammation or indirectly by influencing cardiovascu-
lar risk factors [18,19]. However, reports on the relationship
between DMARDs and CVD are limited, focused on mortality
and predominantly on methotrexate (MTX), and the results are
contradictory [20,21]. Therefore, the present study investi-
gates associations between cardiovascular morbidity and the
use of several conventional DMARDs.
Materials and methods
Patients
Demographic, RA and CVD related data were collected from
613 RA patients by chart review. This sample of RA patients
was randomly taken from the entire RA population registered
in the Jan van Breemen Institute, a large rheumatology outpa-
tient clinic in Amsterdam, the Netherlands. All patients fulfilled
the American College of Rheumatology criteria of RA. Patients
were recruited from time of diagnosis, between 1953 and
2002, onwards until March 2004, the end of the follow up
period.
Study design
A case control study of incident CVD was performed, compar-
ing 72 patients with RA and CVD to 541 RA patients without
CVD. CVD was evaluated from the time of diagnosis of the RA
up to the time of the first cardiovascular event or until the end
of the follow up period.
Cardiovascular disease and risk factors for it
CVD was defined as a verified medical history of coronary, cer-
ebral or peripheral arterial disease. Coronary artery disease
included a history of myocardial infarction, a coronary artery
by-pass graft procedure, a percutaneous transluminal coro-
nary angioplasty or ischemic abnormalities on ECG. Cerebral
arterial disease was defined as a history of cerebral vascular
accident (confirmed by a neurologist), a transient ischemic
attack or a carotid endarterectomy. Peripheral arterial disease
included an aneurysm of the thoracic and/or abdominalis
aorta, a peripheral arterial by-pass operation and amputation of
the (lower) leg. Assessed risk factors for CVD were age, male
sex, hypertension, diabetes, hypercholesterolemia, and smok-
ing habits. Hypertension, diabetes and hypercholesterolemia
were considered to be present if patients received treatment
for these conditions. Smoking habits were recorded as use
ever versus never. All these variables were monitored through-
out the entire disease duration.
Statistical analyses
Comparisons between the various DMARD groups and
between the RA patients with CVD and without CVD were
performed using Students' t-tests and Mann-Whitney U-tests
for continuous variables and Pearson's Chi-square tests for
dichotomic variables.
The dataset was categorized into groups according to the use
ever of sulfasalazine (SSZ), hydroxychloroquine (HCQ) or
MTX, either as monotherapy or as combinations of these drugs
(both sequentially and concurrently in time). The final group
consisted of patients who never used any of the three major
DMARDs; this resulted in a total of eight groups. These groups
were chosen because SSZ, HCQ and MTX are the most com-
monly used drugs and well represented in our random sample
of RA patients.
Logistic regression modeling was used to calculate the odds
ratios (ORs) and 95% confidence intervals (95% CIs) of CVD
for the various DMARD groups simultaneously. In the regres-
sion analysis the group of RA patients who never used SSZ,
HCQ or MTX was used as the reference group with a preset
OR of 1.00.
The first regression model corrected for age, gender, smoking
ever and RA duration. Correcting for age, gender and smoking
was done because these variables are known to be associated
with CVD but not with the use of certain DMARDs. Correcting
for RA duration was done because the chance for a patient to
be treated with more than one DMARD increases the longer
the duration of the disease. As an additional analysis pred-
nisone use ever was added to this first model.
In the second regression analysis we added the presence of
hypertension, diabetes and hypercholesterolemia to the first
model. Adding these known risk factors for CVD was done for
two reasons. Firstly, because these risk factors could be over-
or under-represented in certain DMARD groups and, there-
fore, falsely influence the cardiovascular risk for these groups.
Secondly, correction for known cardiovascular risk factors
was done to explore possible pathways by which the investi-
gated DMARDs can influence cardiovascular risk; for example,
a DMARD could increase the cardiovascular risk by causing
hypertension and this increased risk would disappear after
correcting for hypertension.
A third analysis was done using the first model and adding the
presence or absence of a positive rheumatoid factor test and
erosions on radiographs. This enabled us to calculate the ORs
for CVD associated with these two RA related variables.
The three models described above were also used to explore
if there was any dose dependency in the possible associations
between the DMARD groups and CVD risk. Therefore, we
determined the presence of interactions between any of the
DMARD groups and the maximum used dosages, days of
DMARD use and a cumulative variable. Because the maximum
dosages of the different DMARDs are of different quantities
(for example, 30 mg for MTX and 3,000 mg for SSZ) we cal-
culated the percentage of the maximum dosages allowed by
the Dutch and European medication agencies to be pre-
scribed. For example, 30 mg is the maximum dosage allowedAvailable online http://arthritis-research.com/content/8/5/R151
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to be prescribed for MTX; therefore, if a patient only used 15
mg at the most, we used 50% as the maximum dosage in the
calculations. This way we were able to compare the various
DMARD dosages. As a cumulative variable we calculated the
maximum percentage of the highest prescribable dosage mul-
tiplied by the years this DMARD was used.
A p value of 0.05 or smaller was considered statically signifi-
cant and all tests were performed using the SPSS 12.0 soft-
ware package for Windows (SPSS Inc., Chicago, IL, USA).
Results
Rheumatoid arthritis patients with and without 
cardiovascular disease
The baseline characteristics of the RA patients with and with-
out CVD in our study population are shown in Table 1. The RA
patients with CVD were significantly older (p < 0.001) and
more often male (p = 0.02). Furthermore, they had a longer RA
duration (p < 0.001) and were more likely have a positive IgM
rheumatoid factor test (p = 0.05) and erosion on radiographs
(p = 0.02). The use of DMARDs was also different between
the two groups of RA patients. Patients with CVD had a higher
median number of used DMARDs (p = 0.01). However, the
number of DMARD naive patients and patients who never
used SSZ, HCQ or MTX was also higher in the groups of
patients with CVD (p = 0.002 and p < 0.001, respectively).
Finally, the RA patients with CVD more often had hypertension
and hypercholesterolemia (p < 0.001).
DMARD groups
Various RA and CVD related variables of the entire study pop-
ulation and the different DMARD groups are shown in Table 2.
This table also shows the comparison of these variables
between a DMARD group and the remainder of the study pop-
ulation. The 'only MTX ever' group had a significantly shorter
RA duration (p < 0.001), lower percentage of patients with
erosions (p < 0.001) and a higher percentage of diabetics (p
= 0.002). The 'only SSZ ever' group showed significantly less
erosive patients compared to the remainder of the patients (p
= 0.03). The RA duration of the 'only HCQ ever' group was
longer than that of the other groups (p = 0.01). The percent-
age of patients receiving treatment for hypertension was
higher in the 'SSZ and HCQ ever' group (p < 0.001). In the
'MTX, SSZ and HCQ ever' group, the RA duration was longer
(p = 0.04) and the percentage of erosive patients was higher
(p < 0.001).
Table 1
Characteristics of rheumatoid arthritis patients with and without cardiovascular disease
RA without CVD (n = 541) RA with CVD (n = 72) p value
Demographic variables
Mean age, years (SD) 62 (11) 67 (10) <0.001a
Percentage females 72 58 0.02a
RA related variables
Median disease duration, years (IQ range) 7.7 (5–11) 10.6 (8–13) <0.001a
Percentage IgM-RF positive 70 82 0.05a
Percentage erosive patients 80 92 0.02a
Median number of used DMARDs (IQ range) 2 (2–3) 3 (1–3) 0.01a
Percentage DMARD naive patients 3 10 0.002a
Percentage never SSZ, HCQ or MTX 5 17 <0.001a
Percentage SSZ ever 78 65 0.02a
Percentage HCQ ever 40 38 0.67
Percentage MTX ever 72 44 <0.001a
Percentage prednisone ever 31 25 0.32
CVD related variables
Percentage smoking ever 64 65 0.83
Percentage hypertension 19 49 <0.001a
Percentage diabetes 5 10 0.14
Percentage hypercholesterolemia 2 21 <0.001a
Comparison made using Students' t-tests or Mann-Whitney U tests for the continues variables and Pearson's Chi-square tests for dichotomic 
variables. aSignificant. CVD, cardiovascular disease; DMARD, disease modifying anti-rheumatic drug; HCQ, hydroxychloroquine; IQ range, inter-
quartile-range; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation; SSZ, sulfasalazine.Arthritis Research & Therapy    Vol 8 No 5    van Halm et al.
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Odds ratios for cardiovascular disease
ORs for CVD calculated for three models comparing the vari-
ous DMARD groups to the RA patients who never used SSZ,
HCQ or MTX are presented in Table 3. The first model, cor-
recting for age, gender, smoking ever and RA duration, yielded
significant risk reductions for CVD for the 'only MTX ever', the
'MTX and SSZ ever' and 'MTX, SSZ and HCQ ever' groups.
The second model added additional correction for hyperten-
sion, diabetes and hypercholesterolemia to the corrections of
the first model. This model revealed significant reductions in
risk for CVD for the 'MTX and SSZ ever' and 'MTX, SSZ and
HCQ ever' groups.
The third model, correcting for the same variables as model 1
plus rheumatoid factor positivity and erosions, showed signifi-
cant CVD risk reduction for the 'only MTX ever', 'only SSZ
ever', 'MTX and SSZ ever' and 'MTX, SSZ and HCQ ever'
groups. This third model quantified the ORs for having positive
rheumatoid factor test and erosions on radiographs (OR 2.04
(95% CI 1.02 to 4.07) and OR 2.36 (95% CI 0.92 to 6.08),
respectively), showing RA patients with poor prognostic signs
to have an elevated risk for CVD.
As an additional analysis we added the use ever of prednisone
to the first model, giving an OR for CVD of 0.89 (95% CI 0.48
to 1.65), showing no significant association between corticos-
teroid use and the development of CVD.
Dose dependency
None of the calculated interactions between the DMARD
groups and maximum dosages or the days of DMARD use
Table 2
Rheumatoid arthritis and cardiovascular disease related variables per DMARD-group including associated p values
Groups n (percent) RA related variables (p value) CVD related risk factors (p value)
RA duration Percentage RF Percentage 
erosive
Percentage 
hypertension
Percentage 
diabetes
Percentage 
hypercholesterolemia
Entire group 613 (100) 9 72 82 22 6 4
Never MTX, SSZ or HCQ 37 (6) 12 (0.25) 68 (0.58) 70 (0.06) 24 (0.74) 11 (0.19) 10 (0.11)
Only MTX ever 51 (8) 5 (<0.001)a 61 (0.09) 57 (<0.001)a 12 (0.06) 16 (0.002)a 6 (0.77)
Only SSZ ever 82 (13) 8 (0.29) 70 (0.65) 73 (0.03)a 26 (0.38) 2 (0.16) 9 (0.14)
Only HCQ ever 36 (6) 12 (0.01)a 70 (0.77) 81 (0.85) 17 (0.46) 3 (0.42) 4 (0.96)
MTX and SSZ ever 199 (33) 9 (0.10) 75 (0.18) 85 (0.12) 22 (0.97) 6 (0.80) 1 (0.11)
MTX and HCQ ever 20 (3) 10 (0.83) 75 (0.73) 80 (0.12) 22 (0.97) 6 (0.80) 1 (0.11)
SSZ and HCQ ever 39 (7) 10 (0.39) 69 (0.74) 90 (0.20) 39 (<0.001)a 3 (0.36) 0 (0.35)
MTX, SSZ and HCQ ever 149 (24) 10 (0.04)a 73 (0.63) 91 (<0.001)a 20 (0.56) 5 (0.48) 5 (0.90)
Comparison calculated using a Students' t-tests or Pearson's Chi-square tests, relative to the remainder of the population. aSignificant. 'RA duration' 
is in years; 'Percentage RF' refers to positive test for IgM rheumatoid factor; 'Percentage erosive' refers to erosions on radiographs of hands and/or 
feet. CVD, cardiovascular disease; DMARD, disease modifying anti-rheumatic drug; HCQ, hydroxychloroquine; MTX, methotrexate; RA, rheumatoid 
arthritis; RF, rheumatoid factor; SSZ, sulfasalazine
Table 3
Odds ratios for cardiovascular disease
Groups Model 1 OR (95 percent CI) Model 2 OR (95 percent CI) Model 3 OR (95 percent CI)
Never MTX, SSZ or HCQ (reference) 1.0 1.0 1.0
Only MTX ever 0.16 (0.04–0.66)a 0.47 (0.07–3.23) 0.11 (0.02–0.56)a
Only SSZ ever 0.42 (0.16–1.10) 0.31 (0.07–1.33) 0.37 (0.14–0.99)a
Only HCQ ever 0.55 (0.18–1.67) 0.45 (0.10–2.04) 0.47 (0.15–1.46)
MTX and SSZ ever 0.20 (0.08–0.51)a 0.24 (0.07–0.85)a 0.16 (0.06–0.42)a
MTX and HCQ ever 0.22 (0.04–1.19) 0.54 (0.08–3.66) 0.19 (0.04–1.02)
SSZ and HCQ ever 0.44 (0.14–1.41) 0.34 (0.05–2.16) 0.37 (0.11–1.24)
MTX, SSZ and HCQ ever 0.20 (0.08–0.54)a 0.27 (0.07–0.99)a 0.16 (0.06–0.43)a
Model 1: correcting for age, gender, smoking and rheumatoid arthritis duration. Model 2: identical to 'Model 1' plus correction for hypertension, 
diabetes and hypercholesterolemia. Model 3: identical to 'Model 1' plus correction for a positive rheumatoid factor test and erosions. aSignificant. 
CI, confidence interval; HCQ, hydroxychloroquine; MTX, methotrexate; OR, odds ratio; SSZ, sulfasalazine.Available online http://arthritis-research.com/content/8/5/R151
Page 5 of 6
(page number not for citation purposes)
reached statistical significance (Additional file 1). Moreover,
several interactions between the DMARD groups and the
cumulative variable did reach statistical significance. In models
1 and 3 we found significant interactions for the 'MTX, SSZ
and HCQ ever', the 'MTX and SSZ ever' and the 'SSZ only'
groups. In model 2 just the 'MTX, SSZ and HCQ ever' group
showed a significant interaction with the cumulative variable.
All the observed interactions showed that the cardiovascular
risk for these DMARD groups decreased when the cumulative
DMARD exposure increased (Additional file 1).
Discussion
The present study is the first showing a protective role of
DMARD use for the risk of cardiovascular morbidity in RA
patients. Furthermore, it demonstrates that rheumatoid factor
positivity and joint destruction on radiographs both approxi-
mately double the risk for CVD.
Earlier studies report on associations between DMARDs and
cardiovascular mortality [20,21], the tip of the iceberg, and not
on cardiovascular morbidity as the present paper does. Previ-
ous literature predominantly focused on MTX and, thereby,
ignores the other major conventional DMARDs, such as SSZ
and HCQ. Because a substantial number of RA patients use
DMARDs other than MTX we chose to include these drugs in
our evaluation. Another advantage of the present study is the
fact that several CVD- but also RA-related variables were eval-
uated for their association with CVD.
Mechanisms by which DMARD use could influence the risk for
CVD are poorly investigated. HCQ is reported to influence
cardiovascular risk by lowering total cholesterol levels [19,22].
Corticosteroids are known to cause insulin resistance, hyper-
glycemia, weight gain, fluid retention and hypertension, all
effects that are associated with an increased cardiovascular
risk [23]. The use of MTX can cause a folic acid deficiency with
subsequently higher homocysteine levels and, thereby,
increasing the risk of CVD [20,24]. On the other hand, Choi
and colleagues [21] reported a lower cardiovascular mortality
in RA patients using MTX, which was ascribed to the anti-
inflammatory quality of MTX.
The reduction of CVD-related morbidity in MTX treated
patients is in line with the reduced CVD-related mortality in
these patients as found by Choi and colleagues. The results of
the present study suggest that the use of other conventional
DMARDs, such as SSZ (but not significantly HCQ), is also
associated with a reduction in the risk of developing CVD,
which strengthens the hypothesis that reducing inflammation
is of importance to reduce the risk of CVD. The relationship
between inflammation and cardiovascular risk is furthermore
underlined by the observation that rheumatoid factor positivity
and joint destruction are associated with CVD. These findings
stress the importance of aggressive pro-active treatment of
RA, as this would not only be beneficial for the outcome of the
patients' mobility but could also prevent co-morbidity such as
CVD.
There are some limitations to the present study. First, data
were obtained by chart review; however, this was done sys-
tematically by one observer and classification of CVD was
verified in source documents. Second, there is the possibility
of 'confounding by indication', that is, more severe disease, in
this case indicated by the presence of rheumatoid factor and
erosions on radiographs, was associated with a higher risk of
CVD; however, patients with these characteristics are also
likely to receive more aggressive treatment with DMARDs,
which were found to be associated with a cardiovascular pro-
tective effect. Therefore, confounding by indication may have
biased the results towards null. We can not exclude entirely
such a phenomenon; however, the reported associations
between DMARDs and CVD risk remained present when var-
iables of severity were included in the analyses.
Conclusion
RA patients who are being treated with DMARDs, especially
MTX, have a reduced risk for CVD in comparison with RA
patients who do not use SSZ, HCQ or MTX. We hypothesize
that treatment with MTX, and other conventional DMARDs to
a smaller extent, is associated with less severe atherosclerosis
through suppression of inflammation, which results in a
decreased risk for CVD.
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